Immunogenicity and Safety of Sanofi Pasteur's AVAXIM 80U Pediatric Vaccine Followed by Booster Dose

NCT00483470 Phase 3 COMPLETED

As per request by the Heath Authorities, the present clinical study will assess the immunogenicity and safety

Details

Lead sponsor	Sanofi Pasteur, a Sanofi Company
Phase	Phase 3
Status	COMPLETED
Enrolment	720
Start date	2007-06
Completion	2008-08

Conditions

• Hepatitis A

Interventions

• Hepatitis A vaccine AVAXIM 80U
• Hepatitis A vaccine (HAVRIX 720)

Primary outcomes

• To provide information concerning the immunogenicity of AVAXIM 80U Pediatric vaccine — 1 month post-vaccination

Countries

China